{
    "nct_id": "NCT03250676",
    "official_title": "A Phase 1-2 Multicenter, Open Label Trial of H3B-6545, a Covalent Antagonist of Estrogen Receptor Alpha, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer",
    "inclusion_criteria": "1. Pre- or post-menopausal women.\n2. ER-positive, HER2-negative breast cancer that is advanced or metastatic.\n3. Progressed on prior therapy. Multiple prior lines of therapy allowed in Phase 1 and 2. Participants under amendment 6 (or subsequent amendments) must have received prior cyclin-dependent kinase (CDK4/6) inhibitor therapy. Up to one prior chemotherapy in the metastatic setting is allowed.\n4. A recent archival tumor tissue obtained within 6 months prior to enrollment or a fresh tumor biopsy must be provided. A second biopsy after initiating trial therapy is not required.\n5. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1.\n6. Adequate bone marrow and organ function.\n7. Participants under amendment 6 (or subsequent amendments) must have measurable disease at baseline as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria.\n8. Participants under amendment 6 (or subsequent amendments) must have ESR1 Y537S mutation in absence of ESR1 D538G mutation as per the results of a central laboratory from a Nucleic Acids Whole Blood sample.\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "1. Participants must have at least one measurable lesion.\n2. Participant with inflammatory breast cancer.\n3. Participant has received more than one prior chemotherapy regimen for metastatic disease (Phase 2 only).\n4. Females of childbearing potential who are unable or unwilling to follow adequate contraceptive measures.",
    "miscellaneous_criteria": ""
}